Fact-checked by Grok 2 weeks ago

NAPQI

NAPQI, or N-acetyl-p-benzoquinone imine, is a highly reactive quinone imine compound that serves as the principal toxic metabolite of acetaminophen (also known as paracetamol), a commonly used over-the-counter analgesic and antipyretic drug. Formed in the liver through cytochrome P450-mediated oxidation of acetaminophen—primarily by the enzyme CYP2E1, with lesser involvement from CYP1A2 and CYP3A4—NAPQI accounts for approximately 5–10% of acetaminophen metabolism under normal conditions but increases significantly during overdose when major detoxification pathways (glucuronidation and sulfation) become saturated. In therapeutic doses, NAPQI is swiftly neutralized by conjugation with glutathione (GSH), the liver's abundant tripeptide antioxidant, preventing cellular damage; however, overdose depletes GSH stores, allowing NAPQI to accumulate and exert hepatotoxic effects by covalently binding to sulfhydryl groups on proteins and lipids, thereby initiating oxidative stress, mitochondrial dysfunction, and centrilobular necrosis. This process makes NAPQI central to acetaminophen-induced liver injury, the leading cause of acute liver failure in many countries and a major indication for liver transplantation. Beyond its role in hepatotoxicity, NAPQI's reactivity contributes to extrahepatic effects, including potential damage to kidneys through similar mechanisms of protein adduction and generation, as well as to lungs and auditory cells, though hepatic injury remains the most clinically significant. has elucidated that NAPQI-protein adducts form as early as 1 hour post-overdose, with mitochondrial protein targets playing a key role in amplifying toxicity via ATP depletion and formation, challenging earlier models focused solely on GSH depletion thresholds. The N-acetylcysteine () mitigates NAPQI toxicity by replenishing GSH and directly scavenging the metabolite, with optimal efficacy when administered within 8 hours of ingestion, though it retains benefit up to 24 hours or longer in severe cases. NAPQI's discovery in the 1970s revolutionized understanding of drug-induced , shifting focus from acetaminophen itself to its metabolites and inspiring ongoing studies into CYP enzyme induction (e.g., by or ) as risk factors for toxicity. Despite advances, gaps persist in fully delineating NAPQI's interactions with cellular pathways, such as stress, underscoring the need for targeted therapies beyond to address the global burden of acetaminophen poisoning, including recent 2025 studies on NAPQI's absence in the and novel antidotes like .

Chemistry

Molecular structure

NAPQI, or N-acetyl-p-benzoquinone imine, possesses the molecular formula C₈H₇NO₂ and the IUPAC name N-(4-oxocyclohexa-2,5-dien-1-ylidene). This compound features a characteristic quinone functional group, where a cyclohexadienone ring incorporates conjugated double bonds between positions 2-3 and 5-6, a carbonyl (C=O) at position 4, and an (C=N) linkage at position 1 connected to an acetyl (CH₃C=O) moiety. The extended π-conjugation across the ring and the imine enhances the molecule's reactivity and electronic properties. Compared to its parent compound acetaminophen (N-(4-hydroxyphenyl)acetamide, C₈H₉NO₂), NAPQI results from two-electron oxidation that eliminates the phenolic hydroxyl hydrogen and the nitrogen , transforming the aromatic para-substituted -phenol into a non-aromatic with electrophilic character. NAPQI displays UV-Vis absorption maxima near 400 nm, arising from the extended conjugation in the system, which imparts a color and facilitates its detection in spectroscopic assays. Due to sp² hybridization throughout the , NAPQI adopts a planar with no chiral centers.

Synthesis and reactivity

NAPQI is primarily synthesized in the laboratory through oxidation of acetaminophen. One common method involves enzymatic oxidation using (H₂O₂) in the presence of (HRP), where acetaminophen (0-10 mM) is incubated with 80 nM HRP and 200 µM H₂O₂ in 100 mM ( 7.4) at 25°C for 5 minutes, yielding NAPQI via a one-electron oxidation to the semiquinone intermediate followed by . Another approach is electrochemical oxidation of acetaminophen (0.5 mmol) in a two-compartment with a glassy carbon at 0.30 V vs. in 0.2 M ( 7.0) containing 70% water/30% , allowing controlled generation of NAPQI until the current decays to 5% of its initial value. An alternative chemical route employs (Ag₂O) to oxidize acetaminophen in , producing pure NAPQI that can be isolated and characterized. As a soft , NAPQI exhibits high reactivity toward nucleophiles, primarily through 1,4-Michael addition at its β-carbon. This is particularly evident in its rapid conjugation with thiols, such as (GSH), with a second-order rate constant of $3.2 \times 10^{4} \, \mathrm{M^{-1} s^{-1}} for the spontaneous reaction at physiological conditions. NAPQI is highly unstable in aqueous solutions, with a of less than 1 minute at physiological (7.4), where it undergoes rapid to form acetaminophen or dimerization via radical coupling. Due to this instability, NAPQI is typically stored and handled as stable precursors like acetaminophen, with in situ generation required for most reactivity and analytical studies to avoid decomposition during isolation or storage.

Pharmacology and metabolism

Metabolic formation from acetaminophen

NAPQI, or N-acetyl-p-benzoquinone imine, is primarily formed through the (CYP)-mediated oxidation of (also known as ) in the liver. The main enzymes involved are , which accounts for the majority of this , along with and CYP3A4. These enzymes catalyze the oxidation of acetaminophen to the reactive quinone imine intermediate NAPQI. Under therapeutic doses of acetaminophen (typically 500–1000 mg), only 5–10% of the administered dose is metabolized via this CYP pathway to form NAPQI, with the remainder primarily undergoing (50–60%) or sulfation (25–35%). In cases of overdose, the high-affinity and sulfation pathways become saturated due to their lower capacity, leading to a dose-dependent shift where the CYP-mediated route predominates and NAPQI production increases significantly. The kinetics of this process follow Michaelis-Menten parameters, with exhibiting a Km of approximately 1.3 for acetaminophen, indicating moderate that contributes to the pathway's dominance at higher concentrations. This metabolic formation is predominantly hepatic, occurring in liver microsomes where is highly expressed, though minor extrahepatic production has been observed in tissues like the via activity. Factors such as chronic consumption or can induce expression, enhancing NAPQI formation and thereby increasing the risk of toxicity even at therapeutic doses. The role of a reactive in acetaminophen was first elucidated in the through studies demonstrating covalent binding of radiolabeled acetaminophen to hepatic proteins, linking overdose to oxidative ; subsequent work identified NAPQI as the key intermediate.

detoxification pathways

Under physiological conditions, N-acetyl-p-benzoquinone (NAPQI), the reactive of acetaminophen, is primarily detoxified through conjugation with (GSH) in the liver. This reaction occurs via S-transferase (GST) enzymes, which catalyze the nucleophilic attack of the GSH sulfhydryl group on the electrophilic carbon of NAPQI, forming the glutathione-acetaminophen conjugate (APAP-GSH). Hepatic GSH concentrations, typically ranging from 5 to 10 mM, provide an ample pool for this , ensuring that NAPQI does not accumulate to toxic levels at therapeutic doses. The APAP-GSH conjugate undergoes further processing through the mercapturic acid pathway. It is first cleaved by γ-glutamyl transpeptidase to form the cysteinylglycine conjugate, which is then converted by dipeptidases to the cysteine-acetaminophen conjugate (APAP-CYS). APAP-CYS is subsequently N-acetylated by N-acetyltransferases to yield the N-acetylcysteine-acetaminophen conjugate (APAP-NAC), also known as the mercapturic acid derivative. These polar conjugates are efficiently excreted in the , preventing any residual toxicity. At recommended therapeutic doses of up to 4 g per day in adults, NAPQI production remains well below the liver's capacity, with complete conjugation and elimination occurring without GSH depletion. Toxicity thresholds are generally reached at single doses exceeding approximately 150 mg/kg body weight, beyond which GSH stores may become overwhelmed. To sustain the GSH pool, regenerates GSH from its oxidized form (GSSG) using NADPH as a cofactor, maintaining balance and supporting ongoing . A minor alternative pathway involves the direct non-enzymatic or enzymatically facilitated of NAPQI back to acetaminophen, primarily mediated by NADPH and NADPH-cytochrome P-450 reductase. This reductive route contributes modestly to NAPQI clearance under normal conditions but is insufficient to handle elevated NAPQI levels.

Toxicity

Hepatotoxic mechanism

In acetaminophen overdose, the excessive production of NAPQI rapidly depletes hepatic (GSH) stores, often exceeding 70% loss, which prevents effective and allows unbound NAPQI to accumulate and initiate cellular damage. This depletion primarily affects mitochondrial GSH pools first, creating a vulnerable environment where NAPQI can interact with other cellular components. The unbound NAPQI then undergoes covalent binding to nucleophilic sites on proteins, particularly those in mitochondria such as Complex I subunits of the electron transport chain, forming stable NAPQI-protein adducts that can be detected via immunohistochemistry even before widespread GSH exhaustion. These adducts disrupt mitochondrial integrity by inhibiting electron transport chain function, leading to impaired respiration, severe ATP depletion, and the generation of reactive oxygen species (ROS). The ROS, in turn, promote peroxynitrite formation through interaction with nitric oxide, which further exacerbates oxidative damage to lipids, proteins, and DNA within hepatocytes. This cascade culminates in pathways dominated by oncotic starting in the centrilobular region of the liver lobule, where activity is highest, followed by progression to surrounding if untreated. Activation of c-Jun N-terminal (JNK) signaling contributes to this by translocating to mitochondria and amplifying oxidant stress, while limited occurs alongside regulated involving RIP1 and RIP3 . Research highlights NAPQI's role in activating non-parenchymal cells, such as Kupffer cells and hepatic stellate cells, which drive sterile inflammation through release of damage-associated molecular patterns (DAMPs) and cytokines, amplifying the initial injury. Additionally, a 2025 study in mouse models demonstrates no significant NAPQI penetration into the following hepatotoxic doses, indicating that , if present, arises indirectly from systemic effects rather than direct metabolite exposure.

Clinical poisoning and antidote

Acetaminophen overdose, leading to NAPQI-mediated , typically progresses through three distinct clinical phases in untreated patients. In phase 1 (0-24 hours post-ingestion), patients often experience nonspecific gastrointestinal symptoms such as , , , and diaphoresis, with minimal or no abnormalities in . Phase 2 (24-72 hours) is characterized by the onset of right upper quadrant , tenderness, and rising serum levels ( and ), indicating emerging , though patients may feel relatively well despite these changes. Phase 3 (72-96 hours) marks the peak of , with symptoms including , pruritus, , , and potentially fulminant hepatic failure, which can lead to multiorgan dysfunction if untreated. Diagnosis of NAPQI-related acetaminophen poisoning relies primarily on measuring serum acetaminophen concentrations and plotting them on the Rumack-Matthew , a semilogarithmic graph that predicts risk based on levels obtained at least 4 hours post-ingestion; levels above the treatment line indicate the need for intervention. Elevated liver enzymes (/ >1000 IU/L) and prolonged further support the diagnosis, while emerging research explores serum NAPQI-protein adducts as a sensitive for early detection, though it remains in the investigational stage as of 2025. The primary antidote for NAPQI-induced acetaminophen toxicity is N-acetylcysteine (NAC), administered intravenously or orally to prevent or mitigate by replenishing depleted stores and directly scavenging excess NAPQI. Standard dosing involves a of 150 mg/kg over 1 hour, followed by 50 mg/kg over 4 hours and then 100 mg/kg over 16 hours (total 21-hour protocol), with efficacy approaching 100% if initiated within 8 hours of ingestion. Updated guidelines from 2023 emphasize extended NAC (beyond 21 hours) for late presenters or those with ongoing acetaminophen , such as from extended-release formulations, and supportive care including fluid and for complications. In severe cases meeting —such as arterial <7.3 after or a combination of prothrombin time >100 seconds, >3.4 mg/dL, and grade III/IV —urgent is indicated to improve survival. In the United States, acetaminophen poisoning accounts for approximately 56,000 visits, 2,600 hospitalizations, and about 500 deaths annually, with overall mortality reduced to less than 1% when prompt treatment is provided. Risk factors for severe outcomes include , chronic use, and induction of enzymes, which enhance NAPQI formation and overwhelm detoxification capacity.

References

  1. [1]
    Acetaminophen Toxicity - StatPearls - NCBI Bookshelf
    Apr 10, 2025 · Acetaminophen toxicity is the second most common cause of liver transplantation worldwide and the most common cause of liver failure in the United States.
  2. [2]
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913076/
  3. [3]
    NAPQI (N-acetyl-p-benzoquinone imine) | DrugBank Online
    NAPQI (N-acetyl-p-benzoquinone imine) has the formula C8H7NO2 and an average molecular weight of 149.1467 g/mol. Its IUPAC name is N-(4-oxocyclohexa-2,5-dien-1 ...
  4. [4]
    Oxidation of Acetaminophen to Its Toxic Quinone Imine and ...
    APAP is oxidized by two pathways to form a toxic intermediate, N-acetyl-p-benzoquinone imine (NAPQI), and a nontoxic catechol metabolite, 3-hydroxy-APAP (3-OH- ...
  5. [5]
    (PDF) Mechanisms of acetaminophen oxidation to N-acetyl-P ...
    Sep 19, 2025 · Horseradish peroxidase rapidly catalyzed the H2O2-dependent polymerization of acetaminophen. Acetaminophen polymerization was decreased and ...
  6. [6]
    Electrochemical Synthesis and Kinetic Evaluation of ... - NIH
    It has been shown that N-acetyl-p-benzoquinone-imine (NAPQI) is the main in-vivo and in-vitro oxidation product of acetaminophen (11). Our previous studies show ...
  7. [7]
    Journal of Medicinal Chemistry - ACS Publications
    In-source formation of N-acetyl-p-benzoquinone imine (NAPQI), the putatively toxic acetaminophen (paracetamol) metabolite, after derivatization with ...
  8. [8]
    The spontaneous and enzymatic reaction of N-acetyl-p ... - PubMed
    The spontaneous and glutathione (GSH) transferase catalyzed reactions of GSH and N-acetyl-p-benzoquinonimine (NABQI) have been studied by stopped-flow kinetics.Missing: NAPQI | Show results with:NAPQI
  9. [9]
    Contribution of CYP2E1 and CYP3A to acetaminophen reactive ...
    CYP2E1 accounts for the formation of NAPQI ... Under some conditions, disulfiram may be useful in diminishing the formation of NAPQI after acetaminophen overdose.
  10. [10]
    Acetaminophen bioactivation by human cytochrome P450 enzymes ...
    This study suggests that CYP3A4 is the major CYP enzyme form catalysing acetaminophen oxidation to NAPQI in human liver.
  11. [11]
    Oxidation of acetaminophen to its toxic quinone imine and ... - PubMed
    Apparent Km and Vmax values for the formation of GS-APAP by human P450 2E1 ... Cytochrome P-450 CYP2E1 / metabolism*; Cytochrome P-450 Enzyme System ...
  12. [12]
    Acetaminophen Pathway (therapeutic doses), Pharmacokinetics
    In human liver microsomes, CYP2E1 and CYP1A2 were first reported to convert high doses of APAP to NAPQI [Article:2729995]. Later studies with purified human ...
  13. [13]
    Extrahepatic toxicity of acetaminophen: critical evaluation of ... - NIH
    Here, we review evidence and proposed mechanisms for extrahepatic adverse effects of APAP and weigh weaknesses and strengths in the available data.
  14. [14]
    Role of CYP2E1 in the Hepatotoxicity of Acetaminophen
    This enzyme is also induced by starvation and in uncontrolled diabetes(15, 16). P-450s have been implicated in the hepatotoxicity of acetaminophen (also ...
  15. [15]
    Hepatic, Extrahepatic and Extracellular Vesicle Cytochrome P450 ...
    In this review, we discuss the role of CYP2E1 in the metabolism of alcohol and drugs (with emphasis on acetaminophen), mediating injury/toxicities, and drug- ...
  16. [16]
    Acetaminophen-induced hepatic necrosis. IV. Protective role of ...
    Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. ... 1973 Oct;187(1):211-7. Authors. J R Mitchell, D J Jollow, W Z Potter, J R ...Missing: NAPQI | Show results with:NAPQI
  17. [17]
    Acetaminophen Toxicity: What Pharmacists Need to Know
    Mar 19, 2014 · Single doses of more than 150 mg/kg or 7.5 g in adults have been considered potentially toxic, although the minimal dose associated with liver ...
  18. [18]
    Effect of acetaminophen administration on hepatic glutathione ...
    Our findings suggest that acetaminophen administration selectively depletes (within 2 hr) mitochondrial glutathione, and produces local toxicity by altering ...
  19. [19]
    Mechanisms of acetaminophen hepatotoxicity and their translation ...
    APAP hepatotoxicity is initiated by its conversion to the reactive intermediate NAPQI, which results in glutathione depletion and formation of APAP protein ...
  20. [20]
    NAPQI is absent in the mouse brain after sub-hepatotoxic ... - PubMed
    Jun 1, 2025 · Here, we tested the hypothesis that NAPQI can be generated in the brain by overdosing BTBR T+ Itpr3tf/J (common model of the NDD autism) and ...Missing: penetration | Show results with:penetration
  21. [21]
    Management of Acetaminophen Poisoning in the US and Canada
    Aug 8, 2023 · The original Rumack-Matthew nomogram line, derived from patient data, begins at 200 μg/mL at 4 hours after ingestion. The treatment line (safety ...
  22. [22]
    The Evolution of Circulating Biomarkers for Use in Acetaminophen ...
    Data from clinical trials indicate that APAP-protein adducts are detectable in serum in most people during therapeutic APAP use [82,96,99]. While the adduct ...
  23. [23]
    N-Acetylcysteine - StatPearls - NCBI Bookshelf - NIH
    NAC has FDA approval for treating potentially hepatotoxic doses of acetaminophen (APAP) and is almost 100% effective if given within 8 hours post-ingestion.Missing: 2023 | Show results with:2023